SCHEMBL6726567

SCHEMBL6726567

COc1ccc(-c2noc(C)c2-c2ccc(S(N)(=O)=O)c(F)c2)cc1Cl

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.51
PTGS2 P35354 9/20 0.48
PTGS1 P23219 6/20 0.48
CA4 P22748 2/20 0.47
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
KMT2A Q03164 1/20 0.46
ATM Q13315 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
BRD4 O60885 5/20 0.44
BRD2 P25440 5/20 0.44
BRD3 Q15059 5/20 0.44
CA12 O43570 1/20 0.42
MT-CO2 P00403 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
LMNA P02545 1/20 0.42
CA3 P07451 1/20 0.42
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6722613 0.92 PAX8 (0.54) PAX8PTGS2PTGS1CA4MEN1
SCHEMBL6719439 0.91 PAX8 (0.52) PAX8PTGS2PTGS1MEN1NPC1
SCHEMBL6740093 0.89 PTGS2 (0.52) PAX8PTGS2PTGS1CA4BRD4
SCHEMBL6733469 0.89 PAX8 (0.49) PAX8PTGS2PTGS1CA4MEN1
SCHEMBL6721900 0.88 PTGS2 (0.51) PAX8PTGS2PTGS1CA4MEN1
SCHEMBL6729286 0.87 BRD4 (0.52) PAX8PTGS2PTGS1CA4BRD4
SCHEMBL6720071 0.87 CA4 (0.47) PAX8PTGS2PTGS1CA4
SCHEMBL6730299 0.87 PTGS2 (0.46) PAX8PTGS2PTGS1CA4
SCHEMBL6722734 0.87 PTGS2 (0.46) PTGS2PTGS1CA4
SCHEMBL6722166 0.86 PTGS2 (0.48) PTGS2PTGS1CA4MEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PAX8 3383/4885PTGS2 5/4885PTGS1 4/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PAX8 3355/4885PTGS2 5/4885PTGS1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.